Goodwin Procter advised MOMA Therapeutics on the deal.MOMA Therapeutics announced its completion of a $150 million Series B Financing. MOMA Therapeutics is a biopharmaceutical company discovering…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
